Merus to Participate in Upcoming Investor Conferences
- Ton Logtenberg, CEO, will present at the 2016
Credit Suisse Antibody Dayon Wednesday, September 7at 2:40 PM ETat Credit Suisse'soffices at One Madison Avenuein New York City.
- Management will participate in investor meetings at Citi’s 11th Annual
Biotech Conferenceon Thursday, September 8at the Mandarin Orientalin Boston.
A live webcast of the
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in
N.V. Shelley Margetson– email@example.com +31 (0)30 253 8800 Argot Partners Kimberly Minarovich– firstname.lastname@example.org 1-212-600-1902